CHARLESTON, S.C., Feb. 19, 2021 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests, today announced the closing of its previously announced public offering of 20,509,746 common shares of Aeterna, at a price to the public of $1.45 per share. The gross proceeds from the offering were approximately $29.7 million, before deducting underwriting discounts, commissions and offering expenses payable by Aeterna.

Link:
Aeterna Zentaris Announces Closing of $29.7 Million Bought Deal Offering of Common Shares

Related Post

Leave a comment

Your email address will not be published. Required fields are marked *


Refresh